El Paso, Texas (July 14th, 2025) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today celebrated the 25th anniversary of BD ChloraPrep™ Skin Preparation solution at a celebration at its manufacturing facility.
Since BD ChloraPrep™ Skin Preparation gained initial U.S. Food and Drug Administration (FDA) approval on July 14, 2000, more than seven billion applicators have been distributed globally, and BD ChloraPrep™ Skin Preparation has become the most comprehensive chlorhexidine-alcohol (CHG/IPA) antiseptic skin prep portfolio for pre-surgical and preoperative applications to help reduce bacteria that potentially can cause skin infection.
“This anniversary is especially significant because BD ChloraPrep™ Skin Preparation has such a large positive impact on patients every day – from routine blood draws to lifesaving surgeries,” said Rian Seger, Worldwide president of BD Surgery. “This year alone, we project it will be used 18 times every second. Our team takes great pride and passion in ensuring BD ChloraPrep™ Skin Preparation continues to lead the industry in keeping patients safe with our unwavering commitment to quality and excellence as demonstrated by meeting the USP Monograph standard.”
BD ChloraPrep™ Skin Preparation has been trusted by healthcare providers for more than 25 years demonstrating category leadership through clinical evidence supported by more than 60 peer reviewed studies and is the only CHG/IPA portfolio with products for both pre-surgery and pre-operative procedures with demonstrated antimicrobial persistence for at least seven days. BD ChloraPrep™ Skin Preparation was the first to market with single-sterile applicators with its distinctive Hi-Lite Orange™ tint and the first sterile applicator with sterile solution in the US. Most recently, BD ChloraPrep™ met the newly released United States Pharmacopeia (USP) Monograph for Chlorhexidine Gluconate and Isopropyl Alcohol Topical Solution. USP Monographs reflect the quality attributes of medicines approved by the FDA.
BD ChloraPrep™ Skin Preparation is proudly manufactured in El Paso, where the company employs approximately 800 associates and produces more than 585 million units annually that are shipped to 38 countries around the globe. The 24/7 operation is highly automated to improve efficiency by using advanced assembly and packaging technology and robotics and has two onsite chemistry labs for quality testing. BD El Paso is actively involved in the local community with associates participating in a variety of initiatives to help those in need including Make-A-Wish and the Corazon de Niños program, which helps provide medical care for children born with heart conditions.
Today BD El Paso celebrated this milestone alongside BD executives, local officials and members of the community. BD also presented the El Paso Children’s Hospital Foundation with a grant for the second year in a row. BD’s $30,000 grant will support the Compassionate Care Program at the El Paso Children’s Hospital and Hospital Foundation, helping families bridge the gap between crisis and stability, and enabling children to return home with the support they need to heal.
About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson.
Contacts:
Media: Investors:
Fallon McLoughlin Adam Reiffe
BD Corporate Communications BD Investor Relations
201.258.0361 201.847.6927
Fallon.McLoughlin@bd.com adam.reiffe@bd.com